Drug Discovery and Nonalcoholic Fatty Liver Disease Core

The Drug Discovery and Nonalcoholic Fatty Liver Disease Core provides industry-standard preclinical drug trial studies with complex metabolic, physiologic, and behavioral phenotyping in live mice and consultation to academic and industry biomedical researchers. The Core further provides noninvasive assessment of fatty liver and fibrosis as a measure of nonalcoholic fatty liver disease (NAFL) and nonalcoholic steatohepatitis (NASH) in live mice using a state-of-the-art Vega Wide-field Ultrasound Imaging System (Sonovol). This highly sophisticated system enables multi-axis liver analysis (transverse, lateral, and sagittal) for Shear Wave Elasticity (SWE) imaging to measure liver fibrosis (tissue stiffness) and liver steatosis (tissue brightness). The Core addresses a rising need to identify the next generation of drugs to treat diabetes and its complications and nonalcoholic fatty liver disease (NAFLD) and further understand the pathogenesis of NASH.

Director Bukyung Kim, M.D., Ph.D.  Visiting Professor of Molecular Medicine Associate Professor of Medicine, Division of Endocrinology and Metabolism Albert Sherman Center, 9th Floor West, Suite 1016 (508) 856-8791 bukyung.kim1@umassmed.edu
Co-Director Jae Hyun Kim, M.D., Ph.D. Visiting Professor of Molecular Medicine Associate Professor of Medicine, Division of Gastroenterology Albert Sherman Center, 9th Floor West, Suite 1016 (508) 304-0397 jaehyun.kim21@umassmed.edu
Address: University of Massachusetts Chan Medical School 368 Plantation Street  Albert Sherman Center, 9th Floor West, Suite 1041 Worcester, MA 01605